Show simple item record

dc.contributor.authorKlatte, Tobiasen
dc.contributor.authorRossi, Sabrinaen
dc.contributor.authorStewart, Granten
dc.date.accessioned2018-07-27T14:54:51Z
dc.date.available2018-07-27T14:54:51Z
dc.date.issued2018-12en
dc.identifier.issn0724-4983
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/278512
dc.description.abstractPurpose: Following curative treatment for localised renal cell carcinoma (RCC), up to 30% of patients develop tumour recurrence. Prognostic scores are essential to guide individualised surveillance protocols, patient counselling and potentially in future to guide adjuvant therapy. In metastatic RCC, prognostic scores are routinely used for treatment selection in clinical practice as well as in all major trials. Methods: We performed a literature review on the current evidence base on prognostic factors and models for localised and metastatic RCC. Results: A number of prognostic factors have been identified, of which Tumour Node Metastasis (TNM) classification remains the most important. Multiple prognostic models and nomograms have been developed for localised disease, based on a combination of tumour stage, grade, subtype, clinical features and performance status. However, there is poor level of evidence for their routine use. Prognostic scores for patients with metastatic RCC receiving targeted treatments are used routinely, but have limited accuracy. Molecular markers can improve the accuracy of established prognostic models, but frequently lack external, independent validation. Conclusion: Several factors and models predict prognosis of localised and metastatic RCC. They represent valuable tools to provide estimates of clinically important endpoints, but their accuracy should be improved further. Validation of molecular markers is a future research priority.
dc.description.sponsorshipThe Urology Foundation
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherSpringer Nature
dc.subjectHumansen
dc.subjectCarcinoma, Renal Cellen
dc.subjectKidney Neoplasmsen
dc.subjectNeoplasm Metastasisen
dc.subjectNeoplasm Recurrence, Localen
dc.subjectNeoplasm Stagingen
dc.subjectPrognosisen
dc.subjectChemotherapy, Adjuvanten
dc.subjectTumor Burdenen
dc.subjectSurvival Rateen
dc.subjectNeoplasm Gradingen
dc.subjectBiomarkers, Tumoren
dc.titlePrognostic factors and prognostic models for renal cell carcinoma: a literature review.en
dc.typeArticle
prism.endingPage1952
prism.issueIdentifier12en
prism.publicationDate2018en
prism.publicationNameWorld journal of urologyen
prism.startingPage1943
prism.volume36en
dc.identifier.doi10.17863/CAM.25848
dcterms.dateAccepted2018-04-24en
rioxxterms.versionofrecord10.1007/s00345-018-2309-4en
rioxxterms.versionAM*
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-12en
dc.contributor.orcidKlatte, Tobias [0000-0002-4392-6861]
dc.contributor.orcidRossi, Sabrina [0000-0001-7048-7158]
dc.contributor.orcidStewart, Grant [0000-0003-3188-9140]
dc.identifier.eissn1433-8726
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idUrology Foundation (unknown)
rioxxterms.freetoread.startdate2019-04-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record